Chloe Kent
Reporter
Chloe is an award-winning journalist who has specialized in health reporting throughout her career, with a particular focus on women's health and access to medicine. Before joining Generics Bulletin she worked for B2B publishing consortium Verdict, writing about medical technology and pharmaceuticals. Having graduated from the University of York, she went on to train as a journalist with the Press Association.
Latest From Chloe Kent
US Government Proposals Would Obligate Health Plans To Place Generics On Correct Tiers
The HHS and CMS have proposed that health plans in the US be required to place generic and brand drugs on the correct tiers for their drug category.
Roivant Is Striving Towards New Standards Of Care
With numerous highly anticipated data readouts due over 2023, the spotlight is on Roivant like never before. CEO Matt Gline enlightens In Vivo on the firm’s ‘vant’ subsidiaries, its in-house drug development strategies and the future of its Vtama psoriasis treatment.
PBMs’ ‘Perverse Incentives’ Still Limiting Generics Access, AAM Report Reiterates
Generic medicines continue to be intentionally left off formulary tiers in favor of more expensive brand medications, according to a new report from the US Association for Accessible Medicines.
Generic Mifepristone Manufacturer Sues West Virginia Over Abortion Ban
Generic abortion pill manufacturer GenBioPro has mounted a case in West Virginia alleging that its state-level ban of abortion is unconstitutional, as it is pre-empted by the US Food and Drug Administration’s federal opinion that mifepristone is a safe and legal medication.
Scale Of Off-Patent Savings Ramps Up As Impact Of Biologic LOEs Increases
IQVIA’s latest Global Use of Medicines report demonstrates the impact generics and biosimilars are set to have on global pharmaceutical spending, with losses of exclusivity expected to dampen spending growth over the next five years.
German Generic Reform To Relax Pediatric Pricing
Germany’s Bundesministerium für Gesundheit is reworking the country’s off-patent drug legislation to allow for more flexible pricing.